Feasibility of following up gamma-hydroxybutyric acid concentrations in sodium oxybate (Xyrem®)-treated narcoleptic patients using dried blood spot sampling at home: An exploratory study

CNS Drugs

Volumn 27, Issue 3, 2013, Pages 233-237

  Ingels, Ann Sofie M E ^a   Hertegonne, Katrien B ^b   Lambert, Willy E ^a   Stove, Christophe P ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; OXYBATE SODIUM;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; DRUG EFFECT; FOLLOW UP; HUMAN; MASS FRAGMENTOGRAPHY; NARCOLEPSY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

BELGIUM; DRIED BLOOD SPOT TESTING; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; NARCOLEPSY; SODIUM OXYBATE; SPECIMEN HANDLING;

EID: 84876710145     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0050-5     Document Type: Article

References (19)

1. Andresen H, Stimpfl T, Sprys N, et al. Liquid ecstasy: a significant drug problem. Dtsch Arztebl Int. 2008;105(36):599-603.
2. Andresen H, Sprys N, Schmoldt A, et al. Gamma-hydroxybutyrate in urine and serum: additional data supporting current cut-off recommendations. Forensic Sci Int. 2010;200(1-3):93-9.
3. Carter LP, Pardi D, Gorsline J, et al. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend. 2009;104(1-2):1-10.
4. ® risk management program. Drug Saf. 2004;27(5):293-306.
5. Pardi D, Black J. γ-Hydroxybutyrate/sodium oxybate neurobiology, and impact on sleep and wakefulness. CNS Drugs. 2006;20(12):993-1018.
6. Robinson DM, Keating GM. Sodium oxybate: a review of its use in the management of narcolepsy. CNS Drugs. 2007;21(4):337-54.
7. Ingels ASME, De Paepe P, Anseeuw K, et al. Dried blood spot punches for the confirmation of suspected γ-hydroxybutyric acid intoxications: validation of an optimized GC-MS procedure. Bioanalysis. 2011;3(20):2271-81.
8. Li W, Tse F. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr. 2010;24(1):49-65.
9. De Boer T, Wieling J, Meulman E, et al. Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed Chromatogr. 2011;25:1112-23.
10. Edelbroek PM, Van Der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit. 2009;31(3):327-36.
11. Stove CP, Ingels ASME, De Kesel PMM, et al. Dried blood spots in toxicology: from the cradle to the grave? Crit Rev Toxicol. 2012;42(3):230-43.
12. 2 monitoring in transplant outpatients. J Transplant. 2010;2010:201918.
13. Fokkema MR, Bakker AJ, de Boer F, et al. HbA1c measurements from dried blood spots: validation and patient satisfaction. Clin Chem Lab Med. 2009;47(10):1259-64.
14. Williams SR, McDade TW. The use of dried blood spot sampling in the national social life, health and aging project. J Gerontol B Psycol Sci Soc Sci. 2009;64(Suppl. 1):i131-6.
15. Scharf MB, Lai AA, Branigan B, et al. Pharmacokinetics of gamma-hydroxybutyrate (GHB) in narcoleptic patients. Sleep. 1998;21(5):507-14.
16. Abanades S, Farre M, Segura M, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci. 2006;1074:559-76.
17. ®. Sleep Med. 2009;10(4):490-3.
18. Brenneisen R, Elsohly MA, Murphy TP, et al. Pharmacokinetics and excretion of gamma-hydroxybutyric acid (GHB) in healthy subjects. J Anal Toxicol. 2004;28(8):625-30.
19. Dyer JE. gamma-Hydroxybutyrate: a health-food product producing coma and seizure-like activity. Am J Emerg Med. 1991;9(4):321-4.